-
Mashup Score: 0
The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
When adjusting for sex, the incidence rate for women in 1975 and its 2014 peak were 6.6 cases per 100,000 people and 22.2 cases per 100,000 people, respectively. #hncsm https://t.co/lm9DlpmaUk
-
-
Mashup Score: 1
A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Data from the trial revealed that among patients who were treated for thyroid cancer with or without radioiodine, the EFS rate at 5 years was 94.8% (95% CI, 91.9%-96.7%) vs 93.2% (95% CI, 90.1%-95.4%), respectively. #hncsm https://t.co/Q3s1w1yIoZ
-
-
Mashup Score: 1Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN - 2 month(s) ago
Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
After a median follow-up of 7.2 years, data showed no significant OS improvement with cetuximab/radiotherapy vs radiotherapy alone among all randomly assigned and eligible patients (HR, 0.81; 95% CI, 0.60-1.08; P = .0747). #hncsm | @MitchMachtay https://t.co/UJS2HjDEgl
-
-
Mashup Score: 0
The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“This is the first time in decades where a therapy demonstrated superiority over [SOC] cisplatin-radiotherapy in high-risk patients with [locally advanced] SCCHN,” said Jean Bourhis, MD, PhD. #hncsm https://t.co/xVbKMdC2b9
-
-
Mashup Score: 27Considerations in screening for asymptomatic carotid artery stenosis in irradiated head and neck cancer survivors - 4 month(s) ago
Carpenter et al. add to the body of evidence demonstrating that irradiated head and neck cancer survivors are at high risk for carotid artery stenosis. In this editorial, the concept of screening for…
Categories: General Medicine News, Oncologists1Tweet-
New editorial from @UTSWMedCenter investigators | Considerations in screening for asymptomatic carotid artery stenosis in irradiated head and neck cancer survivors https://t.co/0leIHQwGMd @OncoAlert #HNCSM https://t.co/zorLXQ8gvG
-
-
Mashup Score: 3
While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The increase of the overall cost of cisplatin has persisted even after the resolution of the shortage, highlighting a shift in treatment and a more pronounced financial burden for this patient group. #hncsm | @ASCO https://t.co/jFCZKzEDOk
-
-
Mashup Score: 0
Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Administering pembrolizumab as perioperative therapy reached the primary end point of EFS among patients with stage III or IVA resected locally advanced head and neck squamous cell carcinoma. #hncsm https://t.co/6wrQu25XZQ
-
-
Mashup Score: 9First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC - 6 month(s) ago
Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC @UNC_Lineberger #hncsm https://t.co/EIVrdSNGwJ
-
-
Mashup Score: 3
Follicular dendritic cell sarcoma (FDCS) is an extremely rare malignancy arising from follicular dendritic cells accounting for less than 0.4% of all soft tissu…
Source: journals.sagepub.comCategories: General Medicine News, Hem/OncsTweet-
Nasopharyngeal Follicular Dendritic Cell Sarcoma: Diagnostic Challenges and Therapeutic Management {Case Report} [August 27, 2024] Ghammam et al. Ear, Nose & Throat Journal https://t.co/z1IHHI53tn #hncsm
-
The median follow-up was 2.3 years. The 2-year progression-free survival (PFS) was 50.6% (95% CI, 41.5%-59.8%) in the durvalumab arm vs 63.7% (95% CI, 51.3%-76.1%) in the cetuximab arm (HR, 1.33; 95% CI, 0.84-2.12; P = .89). #hncsm | @henson_md https://t.co/hIUoC4hVqZ